{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T12:42:37Z","timestamp":1791808957331,"version":"4.3.4"},"reference-count":31,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T00:00:00Z","timestamp":1718236800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Background<\/jats:title>\n<jats:p>In real-world studies, the rate of discontinuation of nintedanib (NT) varies from 4% to 53%. Switching anti-fibrotic treatment in patients with idiopathic pulmonary fibrosis (IPF) has not been adequately investigated, and data on the tolerability and efficacy of changes in anti-fibrotic treatment is limited in clinical practice.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To identify factors associated with poor continuation of NT, efficacy and predictors of deterioration after switching from NT to pirfenidone (PFD) in patients with IPF.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Subjects and methods<\/jats:title>\n<jats:p>One hundred and seventy patients with IPF in whom NT was introduced between April 2017 and March 2022 were included to investigate NT continuation status and the effect of switching to PFD.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Results<\/jats:title>\n<jats:p>A total of 123 patients (72.4%) continued NT for 1 year and had a significantly higher %forced vital capacity (FVC) at NT introduction than those who discontinued within 1 year (80.9% \u00b1 16.3% vs. 71.9% \u00b1 22.1%, P = 0.004). The determinant of poor NT continuation was the high GAP stage. On the other hand, 28 of 36 patients who discontinued NT because of disease progression switched to PFD. Consequently, FVC decline was suppressed before and after the change. The predictor of deterioration after the switch was a lower body mass index.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec005\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>In patients with IPF, early NT introduction increased continuation rates, and switching to PFD was effective when patients deteriorated despite initial NT treatment.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0305429","type":"journal-article","created":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T17:53:11Z","timestamp":1718301191000},"page":"e0305429","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":8,"title":["Tolerability and efficacy of switching anti-fibrotic treatment from nintedanib to pirfenidone for idiopathic pulmonary fibrosis"],"prefix":"10.1371","volume":"19","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3688-6782","authenticated-orcid":true,"given":"Keishi","family":"Sugino","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotaka","family":"Ono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikako","family":"Saito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eiyasu","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,6,13]]},"reference":[{"issue":"5","key":"pone.0305429.ref001","doi-asserted-by":"crossref","first-page":"e44","DOI":"10.1164\/rccm.201807-1255ST","article-title":"Diagnosis of idiopathic pulmonary fibrosis. An official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"198","author":"G Raghu","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"pone.0305429.ref002","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1164\/rccm.202202-0399ST","article-title":"Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS\/ERS\/JRS\/ALAT clinical practice guideline","volume":"205","author":"G Raghu","year":"2022","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"pone.0305429.ref003","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1164\/rccm.201006-0894CI","article-title":"Clinical course and prediction of survival in idiopathic pulmonary fibrosis","volume":"183","author":"B Ley","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"pone.0305429.ref004","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1164\/rccm.201308-1483ST","article-title":"An official American Thoracic Society\/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias","volume":"188","author":"WD Travis","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"pone.0305429.ref005","doi-asserted-by":"crossref","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. An update of the 2011 clinical practice guideline","volume":"192","author":"G Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"pone.0305429.ref006","doi-asserted-by":"crossref","first-page":"1601592","DOI":"10.1183\/13993003.01592-2016","article-title":"Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian idiopathic pulmonary fibrosis registry","volume":"49","author":"HE Jo","year":"2017","journal-title":"Eur Respir J"},{"issue":"2","key":"pone.0305429.ref007","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1164\/rccm.201902-0456OC","article-title":"Clinical effectiveness of antifibrotic medications for idiopathic pulmonary fibrosis","volume":"200","author":"TM Dempsey","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"pone.0305429.ref008","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1186\/s12931-018-0845-5","article-title":"The European IPF registry (eurIPFreg): baseline characteristics and survival of patients with idiopathic pulmonary fibrosis","volume":"19","author":"A Guenther","year":"2018","journal-title":"Respir ResJul 28"},{"issue":"2","key":"pone.0305429.ref009","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00127-2018","article-title":"Effects of nintedanib in patients with idiopathic pulmonary fibrosis by GAP stage","volume":"5","author":"CJ Ryerson","year":"2019","journal-title":"ERJ Open Res"},{"issue":"4","key":"pone.0305429.ref010","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00049-2018","article-title":"Safety and tolerability of nintedanib for the treatment of idiopathic pulmonary fibrosis in routine UK clinical practice","volume":"4","author":"SV Fletcher","year":"2018","journal-title":"ERJ Open Res"},{"issue":"2","key":"pone.0305429.ref011","doi-asserted-by":"crossref","DOI":"10.1183\/23120541.00120-2020","article-title":"Time taken from primary care referral to a specialist centre diagnosis of idiopathic pulmonary fibrosis: an opportunity to improve patient outcomes?","volume":"6","author":"CJ Brereton","year":"2020","journal-title":"ERJ Open Res"},{"issue":"4","key":"pone.0305429.ref012","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1183\/13993003.00584-2015","article-title":"Switching to nintedanib after discontinuation of pirfenidone due to adverse events in IPF","volume":"46","author":"K Milger","year":"2015","journal-title":"Eur Respir J"},{"issue":"1","key":"pone.0305429.ref013","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/s12890-019-0841-7","article-title":"Negative impact of anorexia and weight loss during prior pirfenidone administration on subsequent nintedanib treatment in patients with idiopathic pulmonary fibrosis","volume":"19","author":"S Ikeda","year":"2019","journal-title":"BMC Pulm Med"},{"issue":"2","key":"pone.0305429.ref014","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1159\/000448288","article-title":"Insights from the German compassionate use program of nintedanib for the treatment of idiopathic pulmonary fibrosis","volume":"92","author":"F Bonella","year":"2016","journal-title":"Respiration"},{"issue":"2","key":"pone.0305429.ref015","doi-asserted-by":"crossref","first-page":"422","DOI":"10.3390\/jcm9020422","article-title":"Nintedanib treatment for idiopathic pulmonary fibrosis patients who have been switched from pirfenidone therapy: a retrospective case series study","volume":"9","author":"A Vianello","year":"2020","journal-title":"J Clin Med"},{"key":"pone.0305429.ref016","doi-asserted-by":"crossref","first-page":"102099","DOI":"10.1016\/j.pupt.2021.102099","article-title":"Tolerability and efficacy of second-line antifibrotics in patients with idiopathic pulmonary fibrosis","volume":"71","author":"A Cilli","year":"2021","journal-title":"Pulm Pharmacol Ther"},{"issue":"1","key":"pone.0305429.ref017","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1186\/s12890-021-01587-3","article-title":"Switching antifibrotics in patients with idiopathic pulmonary fibrosis: a multi-center retrospective cohort study","volume":"21","author":"Y Suzuki","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"3","key":"pone.0305429.ref018","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1164\/rccm.201604-0801CI","article-title":"Acute exacerbation of idiopathic pulmonary fibrosis. An international working group report","volume":"194","author":"HR Collard","year":"2016","journal-title":"A m J Respir Crit Care Med"},{"issue":"10","key":"pone.0305429.ref019","doi-asserted-by":"crossref","first-page":"684","DOI":"10.7326\/0003-4819-156-10-201205150-00004","article-title":"A multidimensional index and staging system for idiopathic pulmonary fibrosis","volume":"156","author":"B Ley","year":"2012","journal-title":"Ann Intern Med"},{"key":"pone.0305429.ref020","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"KR Flaherty","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"pone.0305429.ref021","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1016\/S2213-2600(20)30355-6","article-title":"Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities","volume":"8","author":"PM George","year":"2020","journal-title":"Lancet Respir Med"},{"issue":"11","key":"pone.0305429.ref022","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.201710-1981ST","article-title":"Recommendations for a standardized pulmonary function report. An official American Thoracic Society technical statement","volume":"196","author":"BH Culver","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"pone.0305429.ref023","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1378\/chest.128.4.2393","article-title":"Pulmonary hypertension in patients with idiopathic pulmonary fibrosis","volume":"128","author":"HF Nadrous","year":"2005","journal-title":"Chest"},{"issue":"1","key":"pone.0305429.ref024","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1186\/s12890-021-01595-3","article-title":"Efficacy of early antifibrotic treatment for idiopathic pulmonary fibrosis","volume":"21","author":"K Sugino","year":"2021","journal-title":"BMC Pulm Med"},{"issue":"5","key":"pone.0305429.ref025","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1007\/s12325-023-02454-9","article-title":"A narrative review of real-world data on the safety of nintedanib in patients with idiopathic pulmonary fibrosis","volume":"40","author":"AJ Podolanczuk","year":"2023","journal-title":"Adv Ther"},{"issue":"4","key":"pone.0305429.ref026","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1007\/s12325-022-02411-y","article-title":"Real-world safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: interim report of a post-marketing surveillance in Japan","volume":"40","author":"T Ogura","year":"2023","journal-title":"Adv Ther"},{"key":"pone.0305429.ref027","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/DDDT.S284819","article-title":"Clinical significance of continuable treatment with nintedanib over 12 months for idiopathic pulmonary fibrosis in a real-world setting","volume":"15","author":"M Kato","year":"2021","journal-title":"Drug Des Devel Ther"},{"key":"pone.0305429.ref028","doi-asserted-by":"crossref","first-page":"1753466619872890","DOI":"10.1177\/1753466619872890","article-title":"Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: a real-world observational study","volume":"13","author":"K Oishi","year":"2019","journal-title":"Ther Adv Respir Dis"},{"issue":"4","key":"pone.0305429.ref029","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.resinv.2023.04.007","article-title":"Elderly idiopathic pulmonary fibrosis patients remain on therapy despite higher incidence of adverse events and dose reductions","volume":"61","author":"A Cilli","year":"2023","journal-title":"Respir Investig"},{"issue":"8","key":"pone.0305429.ref030","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1159\/000508667","article-title":"Older idiopathic pulmonary fibrosis male patients are at a higher risk of nintedanib dose reduction","volume":"99","author":"S Harari","year":"2020","journal-title":"Respiration"},{"issue":"1","key":"pone.0305429.ref031","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.resinv.2020.08.003","article-title":"Tolerability and safety of nintedanib in elderly patients with idiopathic pulmonary fibrosis","volume":"59","author":"Y Uchida","year":"2021","journal-title":"Respir Investig"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0305429","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,13]],"date-time":"2024-06-13T17:53:26Z","timestamp":1718301206000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0305429"}},"subtitle":[],"editor":[{"given":"Yoshiaki","family":"Zaizen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,6,13]]},"references-count":31,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2024,6,13]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0305429","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,13]]}}}